D-1166-2022 Class I Terminated

Recalled by Akcea Therapeutics, Inc. — Carlsbad, CA

Recall Details

Product Type
Drugs
Report Date
July 6, 2022
Initiation Date
May 23, 2022
Termination Date
April 4, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
450 cartons

Product Description

Tegsedi (inotersen) Injection 284 mg/1.5 mL, Rx Only, Sterile solution for Subcutaneous Use, 4 prefilled syringes, each containing 284 mg of inotersen, (equivalent to 300 mg inotersen sodium in 1.5 ml of solution), Distributed by Sobi, Inc. Inc Waltham MA 02451, NDC: 72126-007-01

Reason for Recall

Superpotent: High Out of specification (OOS) test result for percent label claim (%LC).

Distribution Pattern

KY, USA

Code Information

Lots: 028C21AB, 028C21AC, Exp. 05/2025